Samer N. Khader

Samer Khader practices at University of Pittsburgh Physicians - HOPD in Pittsburgh, Pennsylvania.

Samer Khader's NPI, 1912176991, was assigned on February 25, 2008. Samer Khader holds New York license 003020.

Samer Khader's primary practice is University of Pittsburgh Physicians - HOPD, at 2 Hot Metal Street, Pittsburgh, PA 15203.

Samer Khader's primary practice is University of Pittsburgh Physicians - HOPD in Pittsburgh, Pennsylvania. Samer Khader is also affiliated with UPMC Presbyterian. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Samer Khader to 2 more hospitals and 1 medical group, each named with a free account. Samer Khader's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Samer Khader practices, 4 sites in all. Vendor and product names are available with a free account.

Cytopathology is Samer Khader's primary specialty in the NPI Registry, under taxonomy code 207ZC0500X. Samer Khader is licensed in New York.

CMS data shows 924 Medicare services from Samer Khader across 12 procedure codes in 2024, for 320 Medicare patients. Medicare paid $22,196 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 320 Medicare patients who saw Samer Khader in 2024. The largest group is 65 to 74, with 150 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Samer Khader's median patient age at 74, with 32% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Samer Khader for performance year 2024, reported as part of a group. Samer Khader accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Samer Khader from 2 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,815.